Cargando…
Gene therapy for arthritis – where do we stand?
The successful use of biologicals in the treatment of rheumatoid arthritis, psoriatic arthritis and spondyloarthritis has had a major impact on the management of these conditions. The challenge in the development of gene therapy as an alternative to these current treatments is to demonstrate that su...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1297573/ https://www.ncbi.nlm.nih.gov/pubmed/16277696 http://dx.doi.org/10.1186/ar1823 |
_version_ | 1782126218119741440 |
---|---|
author | Chernajovsky, Yuti |
author_facet | Chernajovsky, Yuti |
author_sort | Chernajovsky, Yuti |
collection | PubMed |
description | The successful use of biologicals in the treatment of rheumatoid arthritis, psoriatic arthritis and spondyloarthritis has had a major impact on the management of these conditions. The challenge in the development of gene therapy as an alternative to these current treatments is to demonstrate that such therapy is more advantageous for patients from the therapeutic and safety points of view. Also, it will need to be demonstrated that gene therapy for the arthritides is economically feasible and that patient populations worldwide will be able to access these treatments. |
format | Text |
id | pubmed-1297573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-12975732005-12-01 Gene therapy for arthritis – where do we stand? Chernajovsky, Yuti Arthritis Res Ther Commentary The successful use of biologicals in the treatment of rheumatoid arthritis, psoriatic arthritis and spondyloarthritis has had a major impact on the management of these conditions. The challenge in the development of gene therapy as an alternative to these current treatments is to demonstrate that such therapy is more advantageous for patients from the therapeutic and safety points of view. Also, it will need to be demonstrated that gene therapy for the arthritides is economically feasible and that patient populations worldwide will be able to access these treatments. BioMed Central 2005 2005-09-14 /pmc/articles/PMC1297573/ /pubmed/16277696 http://dx.doi.org/10.1186/ar1823 Text en Copyright © 2005 BioMed Central Ltd |
spellingShingle | Commentary Chernajovsky, Yuti Gene therapy for arthritis – where do we stand? |
title | Gene therapy for arthritis – where do we stand? |
title_full | Gene therapy for arthritis – where do we stand? |
title_fullStr | Gene therapy for arthritis – where do we stand? |
title_full_unstemmed | Gene therapy for arthritis – where do we stand? |
title_short | Gene therapy for arthritis – where do we stand? |
title_sort | gene therapy for arthritis – where do we stand? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1297573/ https://www.ncbi.nlm.nih.gov/pubmed/16277696 http://dx.doi.org/10.1186/ar1823 |
work_keys_str_mv | AT chernajovskyyuti genetherapyforarthritiswheredowestand |